P-114 LIVER TRANSPLANTATION FOR NON-ALCOHOLIC STEATOHEPATITIS: OUTCOMES IN THE MAIN TRANSPLANT CENTER IN PERU

Abstract

Actually, Metabolic associated Fatty Liver Disease (MAFLD) is the most prevalent liver disease in the world and Non-Alcoholic Steatohepatitis (NASH) cirrhosis is the main indication for liver transplantation (LTx). To describe the frequency, characteristics, and outcomes of liver transplantation for patients with NASH in the main transplant center in Lima, Peru. We analyzed data from liver transplant patients from March 2000 to December 2020 using the electronic data. A sample of 89 patients was selected from a total of 286 liver transplants. Inclusion criteria: Patients with Liver biopsy performed 12 months after LTx. Patients under 14 years of age or those who had hepatic steatosis with an etiological diagnosis of virus C or post-transplant alcohol consumption were excluded. The most frequent etiologies of liver cirrhosis in transplant patients in general were NASH, Autoimmune Hepatitis and Alcoholic liver disease: 34.83%, 19.10% and 12.36% respectively, with a mean BMI of 25.68 (SD=4.48). In pre transplant setting: NASH had a BMI of 28.38 (SD=4.44) and those who did not have 24.39 (SD=3.91). 32.58% (n=29). NASH post-transplant recurrence: 23.60% (n=21) and only 8.99% (n=8) mild steatosis. The recurrence of NAFLD and NASH was 62.07% (n=18) and 61.90% (n=13) respectively, while the presentation of NAFLD and NASH de novo was 37.93% (n=11) and 38.10% (n=8). The prevalence of NASH post-liver transplantation is high in Peru. Post-transplant MAFLD/NASH recurrence was higher than de novo cases and BMI was high in this group.